EYEWEAR NOT AFFORDABLE FOR 55% OF BRITISH COLUMBIANS, SPECSAVERS RESEARCH FINDS

2022-08-13 00:31:56 By : Ms. Ada Zhang

Specsavers plans to reverse the trend of British Columbians deprioritizing essential healthcare needs by offering high-quality glasses from $69

VANCOUVER, BC , Aug. 8, 2022 /CNW/ - As rising interest rates and inflation leads to cost of living increases, British Columbians are becoming more price-conscious, and that attitude extends even to necessary health checks.  Specsavers survey, conducted by Research Co., showed that 55% of British Columbians believe prescription eyewear is not affordable1 and many feel that price is a top consideration when purchasing a new pair of glasses (65%), and when selecting an optometry clinic for an eye exam (69%)2.

According to survey results, 56% foresee changing how they approach shopping for prescription eyewear, such as finding a cheaper alternative or avoiding the expenditure altogether when it comes to buying glasses, due to an increasing cost of living in B.C.3 The cost-saving mentality doesn't stop there – almost half (48%) plan to look for ways to minimize or avoid costs associated with having an eye exam altogether4, despite Health Canada's recommendation that adults get their eyes checked at least once every two years5.

"What many don't know is that the vast majority of eye conditions progress with no symptoms and regular eye exams are essential for early detection to ensure vision is protected," said Naomi Barber , Specsavers Director of Optometry. "At Specsavers, every eye exam includes OCT (optical coherence tomography) – a 3D eye scan, as part of a standard eye exam."

"It is clear that the high cost of eyewear is becoming one of the main barriers for people to access comprehensive eyecare, and Specsavers is committed to making sure no one has to put off getting their eyes checked, which is why we offer high quality glasses from $69 ," said Bill Moir , General Manager at Specsavers. "With prescription glasses at other retailers costing between $240 to $1,000 , and premium lenses within the $700 -$1,000 range6, it is not surprising that more than half (55%) of British Columbians feel eyewear is not affordable7."

Specsavers customers receive cost-savings for high-quality frames, including designer lines by Hugo Boss , Liberty, Marc Jacobs , Vivienne Westwood , and more. Thanks to Specsavers vertically integrated supply chain across the world, customers have access to a wide range of high-quality glasses starting at as low as $69 for a complete pair, and progressive glasses from $149 .

"I'm so impressed with the quality of Specsavers glasses and service," said Helen, an 84-year-old North Vancouver resident. "The care and thoroughness made me feel well looked after and gave me comfort. I purchased a pair of designer glasses with transition and progressive lenses for far less than I usually pay for just the prescription alone."

Specsavers is an optometrist-owned and -led company, known in many countries for its high quality and affordable eyewear and accessible eyecare. As part of its goal to redefine accessible eyecare for Canadians, Specsavers offers OCT (optical coherence tomography) – a 3D eye scan, as part of a standard eye exam. The technology has proven to have a measurable impact on the early detection of sight-threatening eye conditions and diseases such as glaucoma and diabetes.

With 17 stores already open in B.C., and a plan to open 50 in the province and 200 across Canada by 2024, Specsavers is focused on increasing store location accessibility, and changing lives through better sight.

Specsavers British Columbia Eye Health Affordability Poll - Fast Facts:

In British Columbia , 65% feel the most important characteristic when purchasing new eyeglasses is price/affordability.

Over half of respondents in British Columbia (52%) claim that inflation and rising costs are impacting purchasing decisions, and 56% feel as though prescription glasses are an expenditure that they seek to spend less on or eliminate altogether. This jumps to 60% for residents in Metro Vancouver.

48% plan to eliminate or reduce costs associated with having an eye exam, and 20% would avoid the expenditure altogether.

The top considerations for British Columbians when selecting an optometry clinic are the affordability of eye exams (69%), convenience of the location (69%) and affordability of eyeglasses and contacts being sold (60%).

One-in-three British Columbians haven't visited their optometrist in the past three years. This is concerning considering Health Canada recommends adults visit every two years. Many eye conditions have no symptoms, and if detected early, vision can be saved.

Founded in the U.K. nearly 40 years ago by optometrist husband and wife team Doug and Mary Perkins , there are now more than 2,500 Specsavers healthcare businesses across 11 countries caring for 41 million patients and customers. Specsavers delivers style, and function with quality eyewear at an affordable price, while using the most advanced clinical equipment as a standard part of eye examinations.

This poll was commissioned by Specsavers, conducted by Research Co. Results are based on an online study conducted from June 14 to June 18, 2022 , among 402 adults in British Columbia who wear glasses or contact lenses. The sample was statistically selected according to Canadian census figures for age and gender in British Columbia . The margin of error—which measures sample variability—is +/- 4.9 percentage points, nineteen times out of twenty.

An earlier poll was commissioned by Specsavers, conducted by Research Co. in February of 2022. Results are based on an online study conducted from February 18 to February 20, 2022 , among 1,009 Canadian adults (incl. 154 respondents from British Columbia ). The data has been statistically weighted according to Canadian census figures for age, gender and region in Canada . The margin of error—which measures sample variability—is +/- 3.1 percentage points, nineteen times out of twenty.

3 https://www2.gov.bc.ca/assets/gov/data/statistics/economy/cpi/cpi_highlights.pdf

5 https://www.canada.ca/en/public-health/news/2018/05/vision-health-month.html

6 https://groupenroll.ca/cost-of-prescription-lenses-in-canada-2021-guide/

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2022/08/c7740.html

UNITY Biotechnology Inc (NASDAQ: UBX) shares are skyrocketing after 12- and 18-week data from its Phase 2 BEHOLD study of UBX1325 for diabetic macular edema (DME). DME is a diabetic complication that affects the blood vessels in the back of your eye. At 18 weeks after a single UBX1325 injection, the mean change in BCVA of UBX1325-treated subjects was an increase of 6.1 ETDRS letters, representing an improvement of +5.0 ETDRS letters compared to sham-treated subjects. Related: UNITY Biotech Stock

Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.

New drugs from Eli Lilly and Novo Nordisk have shown striking results in studies. If insurers step up to back them, the drugs—and the stocks—could take off.

The U.S. Centers For Disease Control and Prevention has relaxed some guidelines around COVID-19, including the quarantine recommendation for people who have been exposed. Officials say the new guidelines are meant to educate people on how to stay safe without causing much disruption to life, school and work.

Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline

Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.

Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).

The FTSE 100 pharmaceutical giant's share price suffered its biggest drop since 1998 on Thursday.

(TSX: CWEB) (OTC: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web," "CW" or the "Company"), the market leader in full-spectrum hemp extract CBD products, today announced plans to unveil a product line catering to the sports vertical. The products are currently undergoing the NSF for Sport® certification process with NSF, a third-party organization that manufacturers, regulators, and consumers look to for the development of public health standards and certification marks that help protect

Vedanta, a microbiome startup that raised $68 million just over a year ago is letting about 20% of its staff go.

The nation's top public health agency relaxed its COVID-19 guidelines Thursday, dropping the recommendation that Americans quarantine themselves if they come into close contact with an infected person. The Centers for Disease Control and Prevention also said people no longer need to stay at least 6 feet away from others.

The "brain health pandemic" since Covid struck exposed a glaring void: Current depression treatments don't fit many patients' needs. A group of biotech stocks hope to change that.

Friends up north and across Tampa Bay snickered when Brian Lafferty revealed where he’d bought a new home. His 30-year-old daughter in Boston called to express concern. Even his ex-wife asked him about it. “Without exception, every person I’ve told I bought a house in The Villages has asked the same thing,” Lafferty said. “‘Isn’t that the STD capital of the United States?’” The Villages, a ...

With CDC relaxing COVID-19 guidelines, you can still shop KN95 face masks for better protection—shop face masks from Amazon, Maskc, Vida and more.

LONDON (Reuters) -Shares in GSK, Sanofi and Haleon fell sharply on Thursday, following declines earlier this week, amid growing investor concerns about U.S. litigation focused on a heartburn drug that contained a probable carcinogen. GSK shares fell more than 10%, Sanofi's stock sagged about 3.3% and Haleon's shares slipped nearly 5% at the close of trading on Thursday. GSK, the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA) have all concluded after experiments that there is no evidence of a causal association between therapy with the heartburn drug ranitidine and the development of cancer in patients, GSK said in a statement in response to the litigation.

US reports surge of 537 monkeypox cases on Wednesday

Dr. Bill Hartman with UW Health joined FOX6 to discuss the latest COVID-19 developments, including the Novavax vaccine.

The Pensacola community has been mourning the death of SCI business director Rodney Jackson from Vibrio. Here's what to know about the bacteria.

After a UBS analyst's note sparked a two-day plunge in the drug makers, their shares rallied Friday after they said there is no evidence the heartburn drug causes cancer.

The latest guidance aligns with the recommendations set for those who are up to date on their COVID-19 vaccines